These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17312299)

  • 1. New insights into oncogene addiction found.
    Garber K
    J Natl Cancer Inst; 2007 Feb; 99(4):264-5, 269. PubMed ID: 17312299
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
    Workman P
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):611-4. PubMed ID: 12503197
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R; Wilcken N; Shannon J
    Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research unveils the 'who' and 'why' of gefitinib.
    Vastag B
    J Natl Cancer Inst; 2004 Sep; 96(18):1352-4. PubMed ID: 15367564
    [No Abstract]   [Full Text] [Related]  

  • 6. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting kinase signaling pathways.
    Boyle SN; Koleske AJ
    Drug Discov Today; 2007 Sep; 12(17-18):717-24. PubMed ID: 17826684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
    Kim R; Toge T
    Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival.
    Maia V; Sanz M; Gutierrez-Berzal J; de Luis A; Gutierrez-Uzquiza A; Porras A; Guerrero C
    Cell Signal; 2009 Jul; 21(7):1229-35. PubMed ID: 19324082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 16-Hydroxycleroda-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis.
    Lin YH; Lee CC; Chan WL; Chang WH; Wu YC; Chang JG
    Toxicology; 2011 Jul; 285(1-2):72-80. PubMed ID: 21530604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Problems in the current target therapy of malignancies].
    Stukov AN; Gershanovich ML; Filov VA; Imianitov EN
    Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022
    [No Abstract]   [Full Text] [Related]  

  • 12. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
    Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B
    Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
    Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidermal growth factor receptor inhibitors: a moving target?
    Bates SE; Fojo T
    Clin Cancer Res; 2005 Oct; 11(20):7203-5. PubMed ID: 16243788
    [No Abstract]   [Full Text] [Related]  

  • 16. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
    Terry J; Lubieniecka JM; Kwan W; Liu S; Nielsen TO
    Clin Cancer Res; 2005 Aug; 11(15):5631-8. PubMed ID: 16061882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia.
    O'Hare T; Eide CA; Deininger MW
    J Natl Cancer Inst; 2008 Jul; 100(13):908-9. PubMed ID: 18577744
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
    Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y
    Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmazie in unserer Zeit 5/2008].
    Dingermann T; Laufer S; Winckler T
    Pharm Unserer Zeit; 2008; 37(5):349. PubMed ID: 18729281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.